NCT00039884

Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?

Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (planned)
• Sponsor: Mirhashemi, Ramin, M.D. · Individual
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a clinical trial (a type of research study) designed to describe the efficacy (effectiveness) and toxicity (safety) of a new medical treatment, NESP (Novel Erythropoiesis Stimulating Protein). This study will be offered to patients with cervical cancer undergoing a combination of chemotherapy and radiation. This treatment may lower your red blood cells. The use of NESP may stimulate the body to produce more red blood cells. Our hypothesis is that higher red blood cells will be beneficial to the patient during treatment for cervical cancer.

Conditions

• Anemia
• Cervix Neoplasms

Interventions

Type	Name	Description
DRUG	NESP - Novel Erythropoiesis Stimulating Protein

Timeline

• Start date: 2001-09-01
• Completion: 2003-03-01
• First posted: 2002-06-17
• Last updated: 2005-06-24

Locations

1 site across 1 country: United States